NEW YORK (GenomeWeb) – NanoString Technologies and Cell Signaling Technology announced today that they are partnering to add CST's highly validated antibodies to NanoString's 3D Biology Protein Profiling Panels.
The companies plan to create new protein-based assays that will expand NanoString's 3D Biology product offerings. Under the terms of the deal, CST will supply antibodies for use in NanoString assays and NanoString will market and sell the assays for use with its nCounter Analysis System.
Further terms of the deal were not disclosed.
3D Biology products allow for the simultaneous analysis of DNA, RNA, and proteins from very small samples, NanoString said. The first product in the line, the RNA: Protein Immune Profiling Panel, was launched in September 2015 and enables simultaneous analysis of 770 RNA targets and 30 protein targets in as few as 150,000 cells. At the time, the company also said it planned to develop companion diagnostics with partners in the pharmaceutical industry.
"Multiplexed analysis of gene and protein expression has the potential to improve the way we diagnose and treat patients with cancer," said CST Chief Scientific Officer Roberto Polakiewicz in a statement. "This agreement is aligned with our platform content enablement initiatives. By working with NanoString, we expect to further the advancement of new biomarkers and better targeted therapies."
The addition of CST's antibodies to the nCounter 3D Biology platform "should enable us to build on our reputation for precise and reproducible data," added Joseph Beechem, NanoString's senior vice president of R&D. "Our customers will benefit from multiplexed, single molecule, digital quantification of proteins with a rapidly expanding menu of assays."